EICHOR

Recruiting studies: Chronic Lymphoid Leukemia

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Safety and Efficacy of KLS-1 Monotherapy in Malignant Neoplasms
Phase 1/Phase 2 · 1 location(s) · Vector Vitale LLC · NCT06506643 Global Trial in APG2575 for Patients With CLL/SLL
Phase 3 · 135 location(s) · Ascentage Pharma Group Inc. · NCT06104566 Venetoclax, Rituximab and Ibrutinib in TN Patients With CLL Undetectable Minimal Residual Disease (uMRD) in Treatment-na
Phase 2 · 1 location(s) · Paolo Ghia · NCT04758975 Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment
Phase N/A · 1 location(s) · OHSU Knight Cancer Institute · NCT06784167 Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Reduced-inten
Phase 2 · 10 location(s) · University of Liege · NCT03852407 Phase Ib Clinical Study of Keynatinib
Phase 1 · 4 location(s) · Medolution Ltd. · NCT04807881 Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL
Phase 1/Phase 2 · 1 location(s) · Medical University of South Carolina · NCT05702853 A Registry for People With T-cell Lymphoma
Phase N/A · 26 location(s) · Memorial Sloan Kettering Cancer Center · NCT05978141 Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT04169737 A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphom
Phase 2 · 31 location(s) · AbbVie · NCT02966756 The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation
Phase N/A · 1 location(s) · Wake Forest University Health Sciences · NCT01890486 Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hem
Phase 2 · 1 location(s) · Fred Hutchinson Cancer Center · NCT07046078 Early Clonal Dynamics During Venetoclax Treatment for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
Phase 2 · 1 location(s) · National Heart, Lung, and Blood Institute (NHLBI) · NCT03986034 Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia / Small
Phase 1 · 1 location(s) · Paolo Caimi, MD · NCT06916767 Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLL
Phase 2 · 11 location(s) · Ascentage Pharma Group Inc. · NCT05147467 Evaluation of Human Immune Responses Vaccination in Patients With Lymphoma
Phase N/A · 2 location(s) · Emory University · NCT03501576 AGMT Austrian CLL (Chronic Lymphocytic Leukemia) Registry
Phase N/A · 9 location(s) · Arbeitsgemeinschaft medikamentoese Tumortherapie · NCT06250465 Pomalidomide After CAR T-cell Therapy for the Treatment of Relapsed or Refractory CD19+ B-cell Leukemia or Lymphoma
Phase 1 · 1 location(s) · University of Michigan Rogel Cancer Center · NCT07532525 Venetoclax as Consolidation in CLL Patients Treated With BTK Inhibitor Monotherapy
Phase 2 · 1 location(s) · The First Affiliated Hospital with Nanjing Medical Universit · NCT06958705 ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis
Phase 2 · 1 location(s) · Leland Metheny · NCT06680661 Long-Term Follow-up of Patients Treated With Miltenyi Cell and Gene Therapies
NA · 7 location(s) · Miltenyi Biomedicine GmbH · NCT06508775 Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype
Phase 2 · 1 location(s) · Roswell Park Cancer Institute · NCT06863402 Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL
Phase 2 · 3 location(s) · Massachusetts General Hospital · NCT04560322 A Phase I Study to Investigate the Tolerability and Safety of ONO-4685 Given as Monotherapy in T Cell Lymphoma and CLL/S
Phase 1 · 14 location(s) · Ono Pharmaceutical Co., Ltd. · NCT06547528 Pirtobrutinib for the Treatment of Elderly Patients With Chronic Lymphocytic Leukemia
Phase 2 · 1 location(s) · Jennifer Woyach · NCT07685717 Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Le
Phase 2 · 8 location(s) · National Cancer Institute (NCI) · NCT07061951 Ibrutinib for the Treatment of AIHA in Patients With CLL/SLL or CLL-like MBL
Phase 2 · 3 location(s) · Gruppo Italiano Malattie EMatologiche dell'Adulto · NCT05694312 A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
Phase 1 · 9 location(s) · Accutar Biotechnology Inc · NCT05780034 A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
Phase 1 · 62 location(s) · Nurix Therapeutics, Inc. · NCT05131022 Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysp
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT02115295

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →